Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with
rheumatoid arthritis in response to disease‐modifying antirheumatic drug treatment and …

Objective Treatment of rheumatoid arthritis (RA) with tumor necrosis factor (TNF)–blocking
agents, including etanercept and infliximab, has resulted in reductions in the radiographic …

Objective To determine whether proinflammatory cytokine treatment or the complete
absence of select cytokines modulates the expression of RANKL and osteoprotegerin (OPG) …

Objective Rheumatoid arthritis (RA) is a chronic inflammatory disease that may result in
debilitating joint deformities with destruction of bone and cartilage. Inflammation is still …

Abstract Objective Spondylarthritis (SpA) and rheumatoid arthritis (RA) have different
patterns of bone damage, with more pronounced bone erosions in RA. The RANK/RANKL …

OBJECTIVE: To further understand the role of osteoprotegerin (OPG) and receptor activator
of nuclear factor-kappaB ligand (RANK-L) in rheumatoid arthritis (RA), we studied the levels …

Rheumatoid arthritis (RA) is characterized by inflammatory synovitis and progressive
destruction of cartilage and bone. While the mechanisms of cartilage destruction in RA have …

Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of
rheumatoid arthritis Page 1 Clinical and Experimental Rheumatology 2008; 26: 240-246 …

OBJECTIVE: To assess the interpatient, interbiopsy, and intrabiopsy variability of receptor
activator of nuclear factor kB ligand (RANKL) and osteoprotegerin (OPG) immunostaining …

Objective Intraarticular corticosteroids are frequently used as successful adjuvant therapy for
inflammatory arthritides, but little is known about their effects on molecules that regulate …